Connect with us


Treed CBD: “Activism is changing and cannabis sits at the heart of that”



Treed CBD was founded on the concept of people taking control of their health

After learning about the history of the hemp plant while studying in LA, Jonathan Stefanni-Machado was inspired to help people take back control of their health and at the same time, become more conscious consumers. 

“We all have that voice in our head telling us that we should do more or do less and it just helped in quieting that voice and allowing me to be more present in the moment,” said Jonathan Stefanni-Machado on his first experiences of CBD, while studying at UCLA in California in 2015.

“I don’t consider myself to be an anxious person but being in the US there was a different culture, a different way of living, and all these small daily stresses to contend with.”

Jonathan Stefanni-Machado

Jonathan was working out five to six days a week at the time, as a semi-professional football player and was recommended CBD for inflammation.

Instead he ended up falling in love with it for how it helped him to get a longer, deeper sleep and quieted his anxieties. 

But it wasn’t until he began researching the history of the cannabis plant that he felt the urge to enter the space himself.

“If you look at the course of human civilisation, we’ve been using cannabis for tens of thousands of years, but for the last 100 years it has been an outlier,” he said.

“I don’t think many people know about its history, that cannabis was a tool that we used to demonise groups of individuals, particularly minority groups and communities of colour.”

He now believes that the emergence of the CBD industry is bringing this knowledge to the fore and educating people about the false stereotypes and misconceptions which have shrouded the plant for decades. 

“CBD has created an opportunity for people to engage with cannabis in ways that they haven’t before,” he continued.

“The stereotypical notion of a ‘stoner’, being a young male, who sits at home on the PlayStation, isn’t an accurate depiction of a cannabis user whatsoever, and we now have all kinds of products which are helping to change the narrative.”

He added: “I think it’s still going to take years to change the stigma, but we’re headed in the right direction.”

Treed CBD, which Jonathan launched with two university friends, was founded out of a desire to empower people to take  a more holistic approach to healthcare. 

“We created Treed to empower individuals to take back control over their health and their happiness, not only through hemp, but plant-based remedies as a whole,” he explained.

But their mission is a much greater one, to help create “conscious consumers”, who aren’t afraid to challenge the status quo.

READ MORE  Study: Cannabis use could affect pregnancy chances

“There’s so many great opportunities in the cannabis space for diversity and inclusion, we have the opportunity to do something with this industry that we haven’t done with previous ones,” said Jonathan.

“Activism is changing, it’s is being done by everyday people who speak up. There is a more of a shift towards consciousness and inclusiveness and I think cannabis sits at the heart of that as an industry.”

He added: “We’re not saying everyone has to run around being social justice warriors, but it’s just about making sure people are informed.”

And as a brand Jonathan believes Treed and others have to take some of the responsibility.

“We’re not saying that what we believe is right or wrong, but there are other narratives and there’s other ways to look at things and we want to present those different ways of looking at things, because we want to develop consciousness consumers,” he added.

“I believe that as tomorrow’s and today’s brands, it’s our responsibility to educate consumers, the reasons why the movement is growing now and to help people understand the things that have shaped the society that we live in today.”

CBD is just the tipping point for Treed, with plans to expand into other plant-based remedies and ride what Jonathan describes as the “psychedelic wave”. 

“We really see the future, as taking a completely different approach towards health and wellness. 

“That will start with cannabis but we’re looking beyond that and developing products like lion’s mane, mushroom blend and capsules, because we really want to be on the sort of mushroom adaptogens and this whole wave of plant remedies.

“There is a whole wave of clinical trials happening looking into how plants such as magic mushrooms can help cure things like post traumatic stress disorder (PTSD) because of their impact on the brain and I believe that all of these natural plant remedies will have a sort of mainstream adoption in the next five to 10 years. 

“Honestly, I just feel like cannabis is just knocking on the door for a whole range of plant-based extracts.”


READ MORE  From alcoholic wine to cannabinoids: one teetotaller's journey to CBD


Study: States with full legal access show fewer registered medical cannabis patients

“If true, this could have implications for public health and policy,” say researchers.



Study shows U.S states where cannabis is legal for recreational purposes have experienced a decrease in patients registering for medical cannabis programmes.

The study on different US states, published in the International Drug Journal, revealed that numbers of registered and active medical cannabis consumers increased while it was not legal for recreational use.

Researchers in Arizona took data from the medical cannabis registry from two dozen states between 2013 and 2020.  These are mandatory registries that record the number of medical cannabis patients. They analysed the data to see if there were any changes around the times that recreational legalisation was introduced.

There are currently 19 states in the US that have legalised recreational cannabis including New Jersey, Vermont, Arizona and New York. However, more states have medical cannabis programs although some are still not operational. Some states such as Colorado have had recreational access since 2012, the year before the study was started.

Medical cannabis patients

The results confirmed that medical cannabis cardholders increased during times when recreational use was not legal. It then subsequently decreased when it became legal.

It also revealed an increase of 380 patients per 100,000 people per year when just medical cannabis was legal. This corresponded to a decrease of 100 patients per 100,000 after recreational cannabis was allowed. The researchers noted that active registered active male patients decreased faster than women. In states where only medical cannabis was legal, the older age groups (35 or older), increased faster.

They also found that in three states with medical-only use, the results showed significant increases in enrollment from 2016 to 2020 across white, African-American and Hispanic patients.

READ MORE  Cannabis may lead to “rebound” headaches in migraine patients - study

The researchers wrote: “There is speculation that enrollment in U.S. state medical cannabis programs differs depending on whether adult recreational cannabis use is legal. If true, this could have implications for public health and policy.”

“Findings suggest that recreational cannabis legalisation is associated with decreasing enrollment in medical cannabis programs, particularly for males.”

Medical Cannabis: A banner advert for subscribing to cannabis health

Continue Reading


Latin American cannabis clinic Zerenia arrives in UK – promising patients more ‘affordable’ access

The clinic has recently joined Project Twenty21 with the promise of making medical cannabis more accessible.



Zerenia clinic: doctor holding medical cannabis
The clinic will initially prescribe for chronic pain and mental health conditions.

Latin American medical cannabis clinic, Zerenia, has launched in the UK, with a bid to improve patient access as it joins Project Twenty21.

Zerenia Clinics, which launched in the UK in recent weeks, has joined a growing number of clinics on Project Twenty21 (T21), as it aims to make medical cannabis more affordable for patients. 

The clinic also offers competitive costs, with consultation fees at £80. 

The clinic’s three doctors will initially prescribe for chronic pain and mental health, with the majority of patients so far seeking treatment for indications such as anxiety, ADHD, PTSD and insomnia.

Zerenia, which already has 14 clinics across Latin America, has treated around 14,000 patients with medical cannabis, and according to Zerenia’s UK clinical operations director, Freeda Solliman, mental health is the predominant indication prescribed for. 

Many of these patients now get their prescriptions funded via private insurers, a model which the clinic now hopes to replicate in the UK. 

“In Latin America we’ve built a body of evidence there to support private insurers to fund medical cannabis treatment,” Solliman told Cannabis Health.

“We’ve seen about 14,000 patients who have been treated with medical cannabis and a large number of those actually get their prescriptions funded by private insurers. That’s the kind of model that you want to bring here.”

Zerenia has partnered with T21, which subsidises the cost of prescriptions, to help build the growing body of evidence for the safety and efficacy of medical cannabis. 

“Our goals are quite well aligned, we want to build the evidence and we want to make medical cannabis more affordable for patients,” continued Solliman.

“We want to work to encourage the NHS first and foremost, but also private insurers to fund at least part of the costs involved in being treated with medical cannabis.”

She added: “We did our research to understand some of the bottlenecks in the industry and how hard it is for some patients to go through the process, so we wanted to support patients through that and try to offer them more of a seamless experience.”

Zerenia is now taking on new patients who wish to join T21, or those who may want to try a different clinic. 

Initial consultations for new patients are priced at £80, for those transfering from a different clinic, £40. Find more information here

READ MORE  Cannabis and IBD - not just a gut feeling?
Continue Reading


CiiTECH to launch medicinal cannabis range Provacan THC in Israel

Israeli patients will have access to the first Provacan THC oil in January 2022, followed by Brazilian and British patients.



CiiTECH: The logo for Ciitech

CiiTECH and Cannassure have announced a major deal to develop and market Provacan THC products for medical cannabis use in Israel.

It marks CiiTECH’s long-awaited move into medicinal cannabis.

In addition to offering established consumer CBD brands, CiiTECH’s flagship brand Provacan is considered one of the most respected in the UK.

Clifton Flack, CEO and founder of CiiTECH, intends to bring Provacan’s reputation for quality and consistency to the troubled Israeli medical cannabis market.

“CiiTECH is unique in its approach to the CBD wellness and medicinal cannabis markets. We built an international reputation as a market-leading CBD company by producing pharmacy trusted CBD oil tinctures and selling them as food supplements before making our move into THC. Our intention is to bring these International standards to the Israeli market,” says Flack.

“As a UK company with strong roots in Israel, CiiTECH is well-positioned to make its THC debut and there is no better place to do so than in Israel, the epicentre of global cannabis research.”

Cannassure is known for producing high-grade medical cannabis in Israel with an advanced indoor-aeroponic growing system and state-of-the-art extraction.”

CiiTECH collaboration

The collaboration with CiiTECH, a leading company in the field of cannabis research and marketing and owner of the leading brand Provacan, is an important step in the field of cannabis oils for us, an area that enjoys significant growth among patients who do not want to consume inflorescence cannabis. We are confident that this collaboration will bring value for us, for CiiTECH and for cannabis patients in Israel, and we believe that it will help us conquer a more significant share of the cannabis oil market in Israel,” said Ran Amir, Cannassure CEO.

READ MORE  Love Hemp hits UK high street

As part of its business strategy, CiiTECH seeks and collaborates with best-of-breed cannabis providers up and down the supply chain in multiple geographies. With this agreement, CiiTECH continues to demonstrate its effective business strategy, commitment to quality assurance, and speed of entry into the market that the industry has grown to expect from CiiTECH.

With the help of Cannassure, CiiTECH will help reform, standardise, educate and establish quality, consistency, and reliability in the Israeli medical cannabis market. In order to achieve this goal, CiiTECH is developing a hybrid solution in which a superior quality product is offered to patients and a unique professional enrichment program is offered to help doctors and pharmacists support patients on a deeper level.

CiiTECH education

Around 80 per cent of Israel’s 100,000 licensed medical cannabis users smoke, rather than using tinctures. The biggest complaint in those groups is the lack of quality and consistency. It is CiiTECH’s mission to show these users how much better tinctures are than smoking. Provacan ambassadors and users will benefit from comprehensive education courses provided by CiiTECH as part of this re-education so they will feel more confident and better supported while using CiiTECH products.

“As cannabis market experts and our involvement in the cannabis ecosystem in Israel, we understand the nature of the demand and the gaps in the Israeli market. Our new THC tincture will revolutionise the lives of many patients who are currently suffering from inconsistencies in the medical cannabis supply chain, and it will be made to the same strict UK and European guidelines as our current products,” concluded Flack.

READ MORE  CBD has positive impact on migraines - study

Israeli patients will have access to the first Provacan THC oil in January 2022, followed soon by Brazilian and British patients.

Ciitech: A banner advertising collaborative content

Continue Reading